Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

Early Phase 1

Completed

Conditions: Primary Myelofibrosis
Secondary Myelofibrosis

Interventions: Drug: Cyclophosphamide
Biological: Filgrastim
Drug: Fludarabine Phosphate
Procedure: Hematopoietic Cell Transplantation
Drug: Melphalan
Drug: Mycophenolate Mofetil
Drug: Tacrolimus
Radiation: Total-Body Irradiation

First Posted Date: 2018-02-08

Last Posted Date: 2020-10-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT03426969

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors

Phase 1

Recruiting

Conditions: Recurrent Malignant Skin Neoplasm
Recurrent Cutaneous Melanoma
Recurrent Malignant Female Reproductive System Neoplasm
Refractory Malignant Male Reproductive System Neoplasm
Refractory Malignant Oral Neoplasm
Recurrent Malignant Pharyngeal Neoplasm
Recurrent Malignant Soft Tissue Neoplasm
Recurrent Malignant Urinary System Neoplasm
Refractory Cutaneous Melanoma
Refractory Malignant Bone Neoplasm

Interventions: Biological: Cord Blood-derived Expanded Allogeneic Natural Killer Cells
Drug: Cyclophosphamide
Drug: Etoposide

First Posted Date: 2018-02-05

Last Posted Date: 2024-11-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 38

Registration Number: NCT03420963

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

Phase 2

Recruiting

Conditions: Non-Small Cell Lung Cancer
Breast Cancer
Ovarian Cancer
Gastrointestinal/Genitourinary Cancers
Endocrine Tumors
Neuroendocrine Tumors
Multiple Myeloma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Aldesleukin
Biological: Individual Patient TCR-Transduced PBL
Drug: Pembrolizumab (KEYTRUDA )

First Posted Date: 2018-01-29

Last Posted Date: 2024-12-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 270

Registration Number: NCT03412877

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling

Phase 2

Recruiting

Conditions: HER2-negative Breast Cancer

Interventions: Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Weekly Paclitaxel
Drug: Trastuzumab
Drug: Pertuzumab
Diagnostic Test: Celcuity CELx HSF

First Posted Date: 2018-01-26

Last Posted Date: 2023-03-06

Lead Sponsor: NSABP Foundation Inc

Target Recruit Count: 64

Registration Number: NCT03412643

Locations: 🇺🇸
Cancer Care Specialists of Central Illinois, Decatur, Illinois, United States
🇺🇸
Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States
🇺🇸
Greater Baltimore Medical Center, Baltimore, Maryland, United States

and more 40 locations

Phase IIb Study Evaluating Immunogenic Chemotherapy Combined with Ipilimumab and Nivolumab in Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer
Hormone Receptor Positive Tumor
Metastatic Breast Cancer

Interventions: Drug: Pegylated liposomal doxorubicin
Drug: Ipilimumab
Drug: Cyclophosphamide
Drug: Nivolumab

First Posted Date: 2018-01-24

Last Posted Date: 2024-10-14

Lead Sponsor: Oslo University Hospital

Target Recruit Count: 82

Registration Number: NCT03409198

Locations: 🇳🇴
Oslo University Hospital, Oslo, Norway
🇳🇴
Stavanger University Hospital, Stavanger, Norway
🇳🇴
Soerlandet Hospital HF Kristiansand, Kristiansand, Norway

and more 3 locations

Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

Phase 2

Active, not recruiting

Conditions: Hodgkin Lymphoma

Interventions: Biological: pembrolizumab
Drug: doxorubicin
Drug: vinblastine
Drug: dacarbazine
Drug: cyclophosphamide
Drug: bleomycin
Drug: vincristine
Radiation: Radiotherapy (RT)
Drug: prednisone/prednisolone
Drug: etoposide

First Posted Date: 2018-01-23

Last Posted Date: 2024-11-20

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 340

Registration Number: NCT03407144

Locations: 🇺🇸
University of Chicago ( Site 0066), Chicago, Illinois, United States
🇺🇸
Cohen Children's Medical Center of New York ( Site 0052), New Hyde Park, New York, United States
🇺🇸
Columbia University/Herbert Irving Cancer Center ( Site 0063), New York, New York, United States

and more 90 locations

BCD With or Without Doxycycline in Mayo Stage II-III Light Chain Amyloidosis Patients

Not Applicable

Completed

Conditions: Amyloidosis; Systemic

Interventions: Drug: Doxycycline
Drug: Bortezomib
Drug: Cyclophosphamide
Drug: Dexamethasone

First Posted Date: 2018-01-17

Last Posted Date: 2021-02-23

Lead Sponsor: Jian Li

Target Recruit Count: 140

Registration Number: NCT03401372

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, China

Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes

Phase 2

Recruiting

Conditions: Acute Biphenotypic Leukemia
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Hematopoietic and Lymphoid Cell Neoplasm
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome
Myelodysplastic Syndrome With Excess Blasts

Interventions: Biological: Dilanubicel
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Thiotepa
Radiation: Total-Body Irradiation
Procedure: Umbilical Cord Blood Transplantation
Other: Laboratory Biomarker Analysis
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspirate
Procedure: Bone Marrow Biopsy
Procedure: Multigated Acquisition Scan
Procedure: Electrocardiography
Procedure: Computed Tomography

First Posted Date: 2018-01-16

Last Posted Date: 2024-11-19

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 35

Registration Number: NCT03399773

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)

Phase 1

Terminated

Conditions: Myxoid/Round Cell Liposarcoma
Multiple Myeloma
Melanoma
Synovial Sarcoma

Interventions: Biological: NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1
Drug: Cyclophosphamide
Drug: Fludarabine
Device: NY-ESO-1 expression testing

First Posted Date: 2018-01-16

Last Posted Date: 2023-06-22

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 3

Registration Number: NCT03399448

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

Phase 3

Completed

Conditions: Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Interventions: Drug: Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.
Biological: Axicabtagene Ciloleucel
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2018-01-05

Last Posted Date: 2024-12-24

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 359

Registration Number: NCT03391466

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States

and more 69 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy